Can cancer vaccines prevent tumor recurrence?

How do cancer vaccines prevent recurrence?

Cancer vaccines work by training your immune system to recognize and attack cancer cells. Unlike traditional vaccines that prevent infections, therapeutic cancer vaccines are designed to target specific proteins (antigens) found on tumor cells. After surgery, there are often microscopic residual cancer cells left behind that can grow into a recurrence. A vaccine can activate T cells—your body's natural killer cells—to hunt down and destroy these remaining cells before they have a chance to form new tumors. This is supported by multiple studies showing that vaccination after tumor removal significantly reduces recurrence rates [2][3][4][5].

One key mechanism is the generation of memory T cells that provide long-term surveillance. In a mouse model of melanoma, a personalized neoantigen vaccine given before surgery (neoadjuvant) produced robust effector memory T cell responses and provided superior long-term protection against tumor rechallenge compared to checkpoint blockade alone [2]. Another study using a nanoparticle E7 vaccine in a head and neck cancer model found that vaccination after tumor removal completely prevented recurrence in 100% of mice, while 60% of unvaccinated mice relapsed [3]. This suggests that removing the primary tumor changes the tumor microenvironment, allowing vaccine-induced immune cells to work more effectively.

What does the evidence show from human trials and animal studies?

The strongest human evidence comes from a phase 2 clinical trial testing a combination of the immune checkpoint inhibitor sintilimab plus a prophylactic HPV vaccine in 13 patients with recurrent or metastatic cervical cancer who had failed standard treatments. The objective response rate was 53.8%—meaning more than half of patients saw their tumors shrink—and the disease control rate was 76.9%. Median progression-free survival was 7.16 months, and median overall survival was not reached after a median follow-up of 16 months [1]. While this is a small trial, it shows that combining a vaccine with immunotherapy can produce meaningful responses even in advanced, treatment-resistant cancers.

Preclinical studies provide even more detailed evidence. In a mouse model of melanoma resistant to checkpoint inhibitors, a personalized neoantigen vaccine given before surgery (neoadjuvant) provided about 70% protection against recurrence on its own, and 90% when combined with anti-PD-1 therapy. In contrast, the same vaccine given after surgery (adjuvant) was ineffective unless combined with anti-PD-1 [2]. This suggests that timing matters: vaccinating before surgery may prime the immune system while the tumor is still present, leading to a stronger response. Another study using a bionic yeast-based vaccine loaded with tumor antigens and an adjuvant cured 57% of mice in a postoperative recurrence model [9]. A hydrogel vaccine implanted after oral cancer surgery in mice prevented local recurrence and metastasis by stimulating immunogenic cell death and activating cytotoxic T cells [8].

Several other studies using different vaccine platforms—including autophagosome-based neoantigen vaccines [4], hybrid membrane vaccines derived from ginseng and tumor cells [5], nanovaccines targeting neoantigens [10], and probiotic-based vaccines [12]—all consistently show that combining vaccination with immune checkpoint inhibitors (like anti-PD-1) significantly reduces postsurgical recurrence and metastasis in mouse models. These studies also demonstrate that vaccines can induce long-term immune memory, protecting against tumor rechallenge months later [2][4][5][10].

What are the limitations and caveats?

While the results are promising, it's important to understand the limitations. Most of the evidence comes from animal models, not large human trials. The only human trial here involved just 13 patients [1], and while the results are encouraging, they need to be confirmed in larger studies. Additionally, not all vaccines work equally well in all settings. For example, a nanoparticle E7 vaccine that was highly effective against TC-1 tumors (a standard model) was much less effective against mEERL95 tumors, which are harder for immune cells to infiltrate [3]. This shows that the tumor microenvironment can limit vaccine effectiveness.

Another challenge is that cancer vaccines often need to be personalized to each patient's tumor, which is complex and expensive. Many of the vaccines studied here are personalized—they use neoantigens or whole tumor lysates from the patient's own tumor [2][4][5][10][11][12]. This makes them highly specific but also logistically demanding. Furthermore, combining vaccines with immune checkpoint inhibitors seems to be necessary for optimal effect in many cases [1][2][4][10][11], which adds cost and potential side effects. The most common side effect in the human trial was hypothyroidism (15.6%), but no severe (grade 3 or above) adverse events were observed [1].

Finally, the field is still evolving. A 2025 review in The Lancet notes that while therapeutic cancer vaccines are showing 'real promise' in clinical settings, especially for melanoma and pancreatic cancer, challenges remain in identifying effective antigens, overcoming immune evasion, and avoiding T-cell exhaustion [6]. Another review highlights that nanotechnology can help overcome some of these barriers by improving antigen delivery and immune activation [7]. So while the answer to 'Can cancer vaccines prevent tumor recurrence?' is increasingly 'yes,' it's a qualified yes—most effective when combined with other immunotherapies, given at the right time (often before or right after surgery), and tailored to the individual's tumor.

About These Sources

This answer is built on 12 peer-reviewed studies — published from 2021 to 2025, 7 from 2024 or later, 12 in Q1 journals, collectively cited 251 times — selected as the most relevant from 15 studies that passed quality screening, drawn from 106 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions